

What more is needed?

In 2005, the global investment in AIDS vaccine R&D was US\$759 million. Although funding for an AIDS vaccine has increased in the recent years, the Global HIV Vaccine Enterprise¹ estimates that the best chance to accelerate R&D efforts requires funding levels closer to US\$1.2 billion per year.

Thus, an increase in global investment of almost US\$450 million annually is necessary to accelerate AIDS vaccine R&D.

Additional funding is needed for:

- Accelerating basic, applied, and clinical science;
- Moving new and existing candidate vaccines into clinical trials;
- Preparing sites and expanding clinical trial capacity in host countries;
- Implementing large-scale clinical trials necessary for regulatory approvals;
- Manufacturing both pilot and bulk lots of vaccine products; and
- Undertaking policy and advocacy activities directed at accelerating AIDS vaccine development and use.

'9 out of 10 EU citizens want the EU to fund additional research into an AIDS vaccine.'

Eurobarometer on HIV prevention – European Commission 2006.

IAVI

IAVI projects total spending for the five-year period 2007-2011 for its own work to be approximately US\$459 million.

¹ Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. PLoS Med 2005; 2 (Issue 2): 111-21.